RXRX
HEALTHCARERecursion Pharmaceuticals Inc - Class A
AI Insight
What's Moving RXRX Today?
No stock-specific AI insight has been generated for RXRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.77$7.18
$3.16
Fundamentals
Market Cap$1.7B
P/E Ratio—
EPS$-1.16
Dividend Yield—
Dividend / Share—
ROE-57.2%
Profit Margin—
Debt / Equity—
Trading
Volume11.2M
Avg Volume (10D)—
Shares Outstanding524.7M
RXRX News
23 articles- Recursion (NASDAQ: RXRX) director receives 88,424-share restricted stock grantStock Titan·Jun 23, 2026
- 1 of the Most Interesting AI Stocks in the Market Isn’t a Tech CompanyBarchart·Jun 23, 2026
- Recursion (NASDAQ: RXRX) director Elaine Sun receives 88,424 restricted stock unitsStock Titan·Jun 23, 2026
- Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market TodayYahoo Finance·Jun 16, 2026
- X-Energy (XE) Powers 13.5% as Cathie Wood Gobbles More StakeYahoo Finance·Jun 16, 2026
- Cathie Wood Buys $444 Million in SpaceX, Dumps Tesla and AMDYahoo Finance·Jun 15, 2026
- Recursion Pharmaceuticals (RXRX) Stock Valuation After AI Drug Discovery And REC-1245 REC-4881 UpdatesYahoo Finance·Jun 13, 2026
- Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?Yahoo Finance·Jun 12, 2026
- Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should KnowYahoo Finance·Jun 10, 2026
- Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?Yahoo Finance·Jun 5, 2026
- Recursion (RXRX) Climbs 9.5% Ahead of Next Week’s Business UpdatesYahoo Finance·Jun 5, 2026
- Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 ResultsYahoo Finance·Jun 4, 2026
- Recursion’s AI Drug Pipeline Progress Tests Investor Patience And ValuationYahoo Finance·Jun 4, 2026
- Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?Motley Fool·Jun 2, 2026
- Recursion to Participate in Upcoming Investor ConferencesYahoo Finance·Jun 2, 2026
- Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesYahoo Finance·May 29, 2026
- Verge, following trial failure, rebrands its AI drug discovery ambitionsBiopharmadive·May 27, 2026
- Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?The Motley Fool·May 25, 2026
- Recursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory?Yahoo Finance·May 24, 2026
- A Look At Recursion Pharmaceuticals (RXRX) Valuation As Mixed Signals Emerge On Future Growth ProspectsYahoo Finance·May 24, 2026
- Morgan Stanley Raises its Price Target on Recursion (RXRX)Yahoo Finance·May 22, 2026
- A Deep Dive Into NVIDIA’s Latest Portfolio MovesMarketbeat·May 19, 2026
- Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech PlatformGlobeNewswire Inc.·Mar 31, 2026
All 23 articles loaded
Price Data
Open$3.10
Previous Close$3.18
Day High$3.27
Day Low$3.09
52 Week High$7.18
52 Week Low$2.77
52-Week Range
$2.77$7.18
$3.16
Fundamentals
Market Cap$1.7B
P/E Ratio—
EPS$-1.16
Dividend Yield—
Dividend / Share—
ROE-57.2%
Profit Margin—
Debt / Equity—
Trading
Volume11.2M
Avg Volume (10D)—
Shares Outstanding524.7M
About Recursion Pharmaceuticals Inc - Class A
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is headquartered in Salt Lake City, Utah.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—